Vaxil Bio Ltd. (VXL.V) Research

Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.

Market snapshot

Symbol
VXL.V
Price
$0.18
Day change
0.00%
Market cap
$493.6K
P/E ratio
1.45x
52-week range
0.13-0.325
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • CENTR Brands Corp. (CNTR.CN)
  • Entheon Biomedical Corp. (ENBI.CN)
  • Universal Ibogaine Inc. (IBO.V)
  • TripSitter Clinic Ltd. (KETA.CN)
  • Global Health Clinics Ltd. (MJRX.CN)
  • Doseology Sciences Inc. (MOOD.CN)
  • Optimind Pharma Corp. (OMND.CN)
  • Steep Hill Inc. (STPH.CN)

Open Vaxil Bio Ltd. (VXL.V) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.